Investment
Features
FeesSafety
Academy
More
Pluang+

Stargate ends support for Gravity, Camp, GOAT, Metis chains by Oct 23, 2026; users must withdraw or bridge funds.

Protocol Fundamentals
19 Oct 2026
Crypto Briefing
View Source
Neutral
Stargate ends support for Gravity, Camp, GOAT, Metis chains by Oct 23, 2026; users must withdraw or bridge funds.

Stargate Finance will stop supporting four low-activity blockchains—Gravity, Camp, GOAT, and Metis—on October 23, 2026. Liquidity providers on these chains must withdraw or bridge their assets before the deadline to avoid losing access. This move is part of LayerZero Labs' broader plan to shut down off-chain infrastructure on underused networks. Additionally, LayerZero's default DVN and Executor services for these chains will end on October 30, 2026, requiring developers to configure alternatives or risk cross-chain features breaking. Stargate v1 pools will fully shut down across all chains by December 15, 2026.

Stargate's plan to end support for Gravity, Camp, GOAT, and Metis by October 23, 2026, sets a clear timeline for users of these blockchains. For readers following the broader cryptocurrency market, here is Pluang's market snapshot as of Oct 20, 2026 03:42 WIB: out of 50 major cryptocurrencies, 46 rose and 3 fell today. Notable movers include EGLD at Rp64.686 (+6.07%) with 57% buy activity, UNI at Rp129.807 (+5.93%) with 66% buy activity, and SNX at Rp3.868 (+5.54%) with 99% sell activity.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App